Empowering TCE and ADC Therapeutics Through Innovative Animal Models

Speech language: Chinese

The development of T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) requires robust, predictive preclinical models to evaluate efficacy, safety, and pharmacodynamics before advancing to clinical trials. This presentation highlights cutting-edge animal model platforms—including genetically engineered mice, humanized immune system models, and patient-derived xenografts (PDX)—tailored for TCE and ADC research. We will discuss strategies to enhance translational relevance, address species-specific limitations, and incorporate real-time pharmacodynamic monitoring. Case studies will demonstrate how optimized animal models can accelerate the transition from discovery to clinical application, ultimately improving therapeutic success rates.

Registration: https://us06web.zoom.us/webinar/register/WN_kfZJt3EuToeyvtXosejSow#/registration